

Ref: 95/SE/LC/2024-25

Date: 12/02/2025

To,  
Head, Listing Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

Head, Listing Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051  
Scrip Symbol: ENTERO

Scrip Code: 544122

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held on February 12, 2025.**

**Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR"), we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e. February 12, 2025, inter alia, considered and approved following:

- 1) The Unaudited Financial Results (Standalone and Consolidated) and Limited Review Report of the Statutory Auditors for the Quarter and Nine Months ended December 31, 2024. The said results are separately disclosed to the Stock Exchanges in the prescribed format.
- 2) Extension of time period for completion of the below mentioned acquisition:

This is with reference to intimations given earlier to Stock Exchanges and pursuant to approval given by the Board of Directors at its Meeting held on November 12, 2024, for acquisition of 100% stake in Radha Swami Medico House, proprietorship firm, through the Company or any one of its subsidiary Company, subject to satisfactory completion of due diligences and execution definitive agreements and fulfilment of conditions therein, if any.

**Revised Indicative time period is as per below:**

Sr. No.	Name of target entity	Revised Indicative time period for completion of the acquisition
1.	M/s. Radha Swami Medico House, a proprietorship firm	March 31, 2025

All the other details except the above revision shall remain same.

- 3) The Board, after considering the recommendation of the Audit Committee, has granted its in-principle approval for subscribing to optionally convertible debentures, to be issued by its existing wholly owned subsidiaries in aggregate up to Rs. 600 crores. Such issuance of optionally convertible debentures by wholly owned subsidiaries to the

Company, as and when carried out, would provide greater flexibility to the Company and its subsidiaries for easier flow of funds between Holding and wholly owned Subsidiary Companies. The necessary disclosures would be provided in the financial statements, as may be applicable.

The Board Meeting commenced at 02:00 PM (IST) and concluded at 04:15 PM (IST).

This outcome will also be uploaded on the website of the Company.

You are requested to take the same on record.

Yours faithfully,  
For **Entero Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President- General Counsel, Company Secretary  
& Compliance Officer**